Skip to main content

Table 2 Demographics and baseline characteristics of patients with COVID-19

From: Clinical and imaging findings of discharged patients with SARS-CoV-2 positive anal swab samples: a descriptive study

  Total (N = 42) Anal swab test positive (n = 6) Anal swab test negative (n = 36) P Valuea
Sex
 Female 25(59.5%) 6(100.0%) 19(52.8%) 0.031
 Male 17(40.5%) 0(0.0%) 17(47.2%)  
Age, median (IQR), y 40(30.8 ~ 46.0) 28.5(13.3 ~ 50.5) 42(32 ~ 46) 0.250
 >50 9(21.4%) 1(16.7%) 8(22.2%) 0.762
 ≤ 50 33(78.6%) 5(83.3%) 28(77.8%)  
BMI, median (IQR) 24.4(22.2 ~ 25.7) 24.6(16.0 ~ 27.9) 24.1(22.2 ~ 25.6) 1.000
Epidemiology
 Direct exposure history 22(52.4%) 2(33.3%) 20(55.6%) 0.148
 Indirect exposure history 6(14.3%) 0(0.0%) 6(16.7%)  
 Family outbreak 14(33.3%) 4(66.7%) 10(27.8%)  
Incubation period, median (IQR), d 7(3 ~ 10) 9(4.5 ~ 11.3) 6.5(3 ~ 10) 0.320
Onset of symptom to, median (IQR), d
 Hospital admission 3.5(2 ~ 6) 3.0(2 ~ 5.5) 3.5(2 ~ 6) 0.697
 Anal swab test 27(25 ~ 32.3) 26.5(21.5 ~ 35.3) 27(25 ~ 32.3) 0.836
Signs and symptoms
 Fever 29(69.0%) 3(50.0%) 26(72.2%) 0.281
 Maximum temperature, median (IQR), °C 37.7(36.8 ~ 38.5) 37.2(36.1 ~ 38.2) 37.9(37.0 ~ 38.7) 0.235
 <37·3 13(31.0%) 3(50.0%) 10(27.8%) 0.541
 37·3–38 14(33.3%) 2(33.3%) 12(33.3%)  
 38·1–39 8(19.0%)) 0(0.0%) 8(22.2%)  
 >39 7(16.7%) 1(16.7%) 6(16.7%)  
 Cough 35(83.3%) 4(66.7%) 31(86.1%) 0.242
 Dyspnea 3(7.1%) 1(16.7%) 2(5.6%) 0.333
 Fatigue 3(7.1%) 1(16.7%) 2(5.6%) 0.333
 Myalgia 5(11.9%) 0(0.0%) 5(13.9%) 0.336
 Headache 4(9.5%) 0(0.0%) 4(11.1%) 0.396
 Nausea and vomiting 1(2.4%) 0(0.0%) 1(2.8%) 0.683
 Diarrhea 6(14.3%) 0(0.0%) 6(16.7%) 0.285
 No symptoms 4(9.5%) 2(33.3%) 2(5.6%) 0.034
Comorbidities
 Diabetes 2(4.8%) 0(0.0%) 2(5.6%) 0.558
 Hypertension 2(4.8%) 0(0.0%) 2(5.6%) 0.558
 Hepatitis or liver cirrhosis 2(4.8%) 0(0.0%) 2(5.6%) 0.558
 Chronic renal failure 1(2.4%) 0(0.0%) 1(2.8%) 0.683
 Malignancy 1(2.4%) 0(0.0%) 1(2.8%) 0.683
 Digestive diseases 3(7.1%) 1(16.7%) 2(5.6%) 0.333
Clinical type
 Mild type 2(4.8%) 1(16.7%) 1(2.8%) 0.701
 Common type 30(71.4%) 3(50.0%) 27(75.0%)  
 Severe type 7(16.7%) 2(33.3%) 5(13.9%)  
 Critical type 3(7.1%) 0(0.0%) 3(8.3%)  
 Mild + Common type 32(76.2%) 4(66.7%) 28(77.8%) 0.558
 Severe + Critical type 10(23.8) 2(33.3%) 8(22.2%)  
Treatment
 Antibiotic 29(69.0%) 3(50.0%) 26 (72.2%) 0.281
 Duration of antibiotic 6.5(0 ~ 8.3) 2.5(0 ~ 10.5) 7.0(0 ~ 8) 0.562
 Glucocorticoid 29(69.0%) 4(66.7%) 25(69.4%) 0.892
 Duration of glucocorticoid 4(0 ~ 5) 4.5(0 ~ 6.5) 4(0 ~ 5) 0.739
 Non-Invasive Ventilation 3(7.1%) 1(16.7%) 2(5.6%) 0.333
 Duration of throat swab positive, median (IQR), d 7.5(5 ~ 10.3) 10.0(7.3 ~ 12.3) 7.0(3 ~ 10) 0.208
 Duration of fever, median (IQR), d 5(0.8 ~ 9.3) 1(0 ~ 6.3) 6(2 ~ 9.8) 0.120
 Duration of major symptoms (except fever), median (IQR), d 8.5(3.8 ~ 13.3) 4.5(0 ~ 5.5) 10.5(4.3 ~ 14) 0.022
 Hospital stays, median (IQR), d 12.5(9 ~ 18) 14.5(11 ~ 20.3) 11.5(9 ~ 17.5) 0.471
  1. a P values indicate differences between anal swab test positive and negtive patients. P < .05 was considered statistically significant